partners
-
Strategic Business Partnerships
-
-
上海南方模式生物科技股份有限公司 -
北京百普塞斯生物科技股份有限公司 -
上海泰坦科技股份有限公司 -
北京義翹神州科技股份有限公司 -
杭州奕安濟(jì)世生物藥業(yè)有限公司 -
上海益諾思生物技術(shù)股份有限公司 -
康龍化成（成都）臨床研究服務(wù)有限公司 -
煙臺(tái)邁百瑞國(guó)際生物醫(yī)藥股份有限公司 -
杭州泰格醫(yī)藥科技股份有限公司 -
杭州思默醫(yī)藥科技有限公司 -
普蕊斯（上海）醫(yī)藥科技開(kāi)發(fā)股份有限公司 -
上海康德弘翼醫(yī)學(xué)臨床研究有限公司 -
上海生生物流有限公司 -
方達(dá)制藥（蘇州）有限公司 -
華東醫(yī)藥股份有限公司 -
北京映急醫(yī)藥冷鏈科技有限公司 -
南京金斯瑞生物科技有限公司 -
北京擎科生物科技股份有限公司 -
蘇州金唯智生物科技有限公司 -
上海藥明津石醫(yī)藥科技有限公司 -
圣蘭格（北京）醫(yī)藥科技開(kāi)發(fā)有限公司 -
廣州金墁利醫(yī)藥科技有限公司 -
北京泛生子基因科技有限公司 -
觀瀾網(wǎng)絡(luò)（杭州）有限公司
-
Our Strategic Collaboration Models
Welcome to contact us to explore potential cooperation opportunities
-
License OutCentryMed offers licensing opportunities for its innovative TCE pipeline, targeting malignant tumors. We provide flexible licensing options, including exclusive and regional agreements, to facilitate clinical development and commercialization.
-
Platform-Based CollaborationWe specialize in the design and development of multifunctional T-cell engagers (TCEs), enabling flexible collaboration models across discovery, optimization, and preclinical validation. By integrating deep expertise in immuno-oncology with advanced protein engineering, we deliver tailored solutions to accelerate first-in-class and best-in-class drug development.
-
Co-Development & Early-stage ResearchWith comprehensive R&D capabilities, CentryMed seeks co-development and early-stage research partnerships. Byintegrating resources and technical expertise, we aim to enhance drug development efficiency and jointly advance clinical and commercialization processes.
-
Investment & New VenturesCentryMed actively collaborates with investment institutions, industry partners, and entrepreneurial teams to incubate innovative ventures. We offer technical support, R&D resources, and market insights, leveraging our industry network to help early-stage projects grow rapidly and drive breakthroughs in the biopharmaceutical field.